Compare · BJDX vs BSX
BJDX vs BSX
Side-by-side comparison of Bluejay Diagnostics Inc. (BJDX) and Boston Scientific Corporation (BSX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BJDX and BSX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.39B, about 13376.1x BJDX ($5.4M).
- Over the past year, BJDX is down 34.3% and BSX is down 51.3% - BJDX leads by 17.1 points.
- BSX has been more active in the news (12 items in the past 4 weeks vs 11 for BJDX).
- BSX has more recent analyst coverage (25 ratings vs 1 for BJDX).
- Company
- Bluejay Diagnostics Inc.
- Boston Scientific Corporation
- Price
- $5.22+0.00%
- $48.71+0.31%
- Market cap
- $5.4M
- $72.39B
- 1M return
- +179.14%
- -13.91%
- 1Y return
- -34.26%
- -51.31%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 11
- 12
- Recent ratings
- 1
- 25
Bluejay Diagnostics Inc.
Bluejay Diagnostics, Inc., an in-vitro diagnostic company, develops, manufactures, and markets minimally invasive point-of-care (POC) diagnostics tests and devices for infectious disease, inflammation, and oncology markets in the United States. It is developing Symphony biomarker detection platform for the detection of sepsis, cancer, cardiac ishcemia, and congestive heart failure. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. It has a collaboration agreement with Toray Industries, Inc. to develop a point of care test for covid-19 patient triage; and a research and development agreement with Naval Medical Research Center to develop lateral flow rapid test for diagnosis of various tick-borne diseases, including Lyme disease. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BJDX
- Bluejay Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- SEC Form SCHEDULE 13G filed by Bluejay Diagnostics Inc.
- Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
- Bluejay Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership
- Director Wurth Douglas Clark bought $25,000 worth of shares (12,500 units at $2.00) (SEC Form 4)
- President and CEO Dey Indranil bought $25,000 worth of shares (12,500 units at $2.00), increasing direct ownership by 56,818% to 12,522 units (SEC Form 4)
- Director Chase Donald R bought $25,000 worth of shares (12,500 units at $2.00), increasing direct ownership by 50,000% to 12,525 units (SEC Form 4)
- Director Zeidman Fred S bought $25,000 worth of shares (12,500 units at $2.00) (SEC Form 4)
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits